Exclusivity For Biologics, Drugs Should Be The Same After All, Grabowski Says

Duke University economics professor Henry Grabowski and his colleagues suggest the Hatch-Waxman statute be revised to mirror biosimilars legislation and provide 12 years of market exclusivity.